(19)
(11) EP 2 787 345 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.04.2016 Bulletin 2016/15

(45) Mention of the grant of the patent:
24.02.2016 Bulletin 2016/08

(21) Application number: 14168748.3

(22) Date of filing: 16.05.2007
(51) International Patent Classification (IPC): 
G01N 33/53(2006.01)
G01N 33/573(2006.01)
 G01N 33/567(2006.01)
A61K 31/435(2006.01)

(54)

TREATMENT OPTIONS FOR FABRY DISEASE

BEHANDLUNGSOPTIONEN FÜR MORBUS FABRY

OPTIONS DE TRAITEMENT POUR LA MALADIE DE FABRY

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 16.05.2006 US 801089 P
23.10.2006 US 853631 P

(43) Date of publication of application:
08.10.2014 Bulletin 2014/41

(60) Divisional application:
15173515.6 / 2955520

(62) Application number of the earlier application in accordance with Art. 76 EPC:
07797506.8 / 2024745

(73) Proprietor: Amicus Therapeutics, Inc.
Cranbury, NJ 08512 (US)

(72) Inventors:
  • Lockhart, David
    Cranbury, NJ 08512 (US)
  • Castelli, Jeff
    Cranbury, NJ 08512 (US)

(74) Representative: Miller Sturt Kenyon 
9 John Street
London WC1N 2ES
London WC1N 2ES (GB)


(56) References cited: : 
WO-A1-99/62517
 WO-A2-2004/074450
   
  • YAM GARY HIN-FAI ET AL: "Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants", AMERICAN JOURNAL OF PHYSIOLOGY - CELL PHYSIOLOGY, vol. 290, no. 4, April 2006 (2006-04), pages C1076-C1082, XP002566496, ISSN: 0363-6143
  • SHIN S H ET AL: "Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone", PHARMACOGENETICS AND GENOMICS 2008 LIPPINCOTT WILLIAMS AND WILKINS GBR, vol. 18, no. 9, September 2008 (2008-09), pages 773-780, XP002566495,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).